Prescribing guide
Amvuttra (vutrisiran)For ATTR-CM: dosing, vitamin A, site of care and prior authorization criteriaFor prescribers and their offices treating ATTR amyloidosis with cardiomyopathy: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. A Start Form to Alnylam Assist signed by patient and prescriber, which also carries the prescription; prior authorization; a site of care, from office or infusion center to home nursing where coverage allows; administration by a healthcare professional.
Example PA threshold
Cigna example: age 18 or older, diagnosis by technetium pyrophosphate scintigraphy, TTR-typed biopsy or pathogenic TTR variant, cardiac involvement on imaging, heart failure short of NYHA class IV, cardiologist or amyloidosis specialist, no concurrent tafamidis, Attruby or silencer.
Monitoring
No labs required by the label; vitamin A supplementation at the RDA, not titrated to serum levels; ophthalmology referral for ocular symptoms suggestive of deficiency, such as night blindness.
Support line
Alnylam Assist, 1-833-256-2748, Monday to Friday, 8 AM to 6 PM; a Case Manager within 2 business days of the Start Form, a commercial copay program with an annual cap, one Quick Start dose when a new patient's PA is denied or pending 7 days, a Bridge Program for coverage changes, and a PAP mainly for the uninsured.
Give your patient their plan
A one-page handout for starting Amvuttra, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/amvuttraBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Submit the Start Form | Pages 1 and 2, signed by patient and prescriber, faxed to 1-833-256-2747 or submitted online. It doubles as the prescription: 25mg subcutaneous every 3 months, quantity one prefilled syringe, with refills. Name, office, Tax ID, NPI, phone and address are required or the form cannot be processed. ICD-10 codes on the form are E85.82 for wild-type and E85.4 for hereditary ATTR-CM. | Start Form |
| Benefit verification | An Alnylam Case Manager sends a summary of benefits to the office and the patient within 2 business days of the Start Form. The Field Reimbursement Team answers coverage, coding and reimbursement questions and supports prior authorization and appeals; it reaches out after a Start Form or through an Alnylam sales representative. | Alnylam Assist HCP teams |
| Choose a site of care | Administration may occur in an office, a local clinic, or the patient's home if covered by insurance. Alnylam's guide says home treatment should follow the prescriber's evaluation and may not be covered by all plans. | Administration Guide |
| Home nursing | The Start Form has an optional At Home Nursing Order box authorizing home nursing to educate and to give the subcutaneous dose as prescribed. | Start Form |
| Acquisition | Specialty distributor McKesson Specialty or McKesson Plasma and Biologics; specialty pharmacies Accredo, CVS Specialty and Orsini. NDC 71336-1003-1, one 25mg/0.5mL prefilled syringe per carton. Alnylam lists a WAC of $119,351 per syringe. | Product Characteristics |
| Quick Start when the PA stalls | For new patients not yet on therapy, with a PA, pre-determination or similar denied or pending for at least 7 calendar days after submission. A Start Form must already be in. A licensed provider signs the Quick Start form and faxes it to 1-833-256-2747; one dose ships if the patient qualifies. | Quick Start form |
| Copay program terms | Commercial insurance only, with an annual benefit cap; the patient pays once the cap is reached in a calendar year. Not valid under Medicare, Medicaid, TRICARE, VA, DoD, IHS or other federal or state programs, or when the product is not covered. Its terms say the value is meant to count toward patient out-of-pocket obligations, including under accumulator or maximizer programs. Patients 18 or older; pharmacist questions go to CapitalRx at 1-844-306-9173. | Copay terms |
| Counsel on vitamin A | Instruct the patient to take the RDA of vitamin A, not more, and to report ocular symptoms such as night blindness. Ask about multivitamins already in use. The label gives no start day for the supplement. | FDA label |
| Pregnancy | No data in pregnant women. The label asks patients to report pregnancy or plans for it, and notes that both vitamin A deficiency and excess affect embryofetal development. Rat studies showed fetal toxicity only at maternally toxic doses. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, April 15, 2026. Approval a year at a time. The policy lists no separate renewal criteria for the heart use. This policy was reviewed in March 2026, after the March 2025 label added the heart use. Its ban on combining with tafamidis or Attruby is the plan's rule, not the label's, and 40% of patients in the HELIOS-B trial were already on tafamidis. The federal employee Blue Cross policy from April 2026 asks for other things. Those include an NT-proBNP of 600 or more, a heart failure history, and a genetic test or biopsy. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | ATTR-CM, wild-type or hereditary, age 18 or older | Diagnosis note and imaging; Cigna names no ICD-10 codes | Cigna policy |
| Confirmation | Technetium pyrophosphate scintigraphy, or a tissue biopsy with TTR typing by mass spectrometry, immunoelectron microscopy or immunohistochemistry, or a pathogenic TTR variant by genetic testing | Scan report, pathology report or genetic test report | Cigna policy |
| Cardiac involvement | Diagnostic imaging showing it, for example increased ventricular wall or septal thickness | Echocardiogram or cardiac MRI report | Cigna policy |
| Heart failure and class | Heart failure present, NYHA class IV excluded | Functional class and heart failure history in the note | Cigna policy |
| Prescriber | Cardiologist or a physician who specializes in amyloidosis, prescribing or consulting | Specialty on the request | Cigna policy |
| Combination | No concurrent Attruby, tafamidis, Onpattro, Tegsedi or Wainua; Cigna treats concurrent use as not medically necessary | Current medication list; a stop date if switching | Cigna policy |
| Dose | 25mg subcutaneous, no more often than once every 3 months | Order and administration record | Cigna policy |
| Other plans | FEP Blue, effective April 1, 2026, confirms the diagnosis by genetic test or tissue biopsy only, with no scan option, and adds septal thickness over 12mm, a heart failure hospitalization or diuretic-requiring volume overload, NT-proBNP of 600 pg/mL or more, and no AL amyloidosis; renewal needs improvement or stability, such as fewer hospitalizations or a better 6MWT or KCCQ-OS | Echo, NT-proBNP, hospitalization history and the light-chain workup | FEP Blue policy |
Amvuttra dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | 25mg (0.5mL) by subcutaneous injection, administered by a healthcare professional. Single-dose prefilled syringe, 29-gauge needle with a needle shield. | FDA label |
| Every 3 months | 25mg; no titration and no dose adjustment for age 65 or older, mild or moderate renal impairment (eGFR 30 to under 90), or mild or moderate hepatic impairment. Not studied in severe renal impairment, ESRD, severe hepatic impairment or after liver transplant. | FDA label |
| Missed dose | Administer as soon as possible, then resume every 3 months from the most recently administered dose. | FDA label |
| Preparation | If stored cold, warm to room temperature for 30 minutes. Inspect for discoloration or particles; do not use a dropped or damaged syringe. Store at 2 to 30 degrees C (36 to 86 degrees F) in the carton; do not freeze. | FDA label |
| Injection | Abdomen, thighs or upper arms, avoiding 5cm around the navel and scarred, red, inflamed or swollen skin. Pinch, insert fully at 45 to 90 degrees, push the plunger to the end to activate the shield. | FDA label |
| Premedication and observation | Neither required; Alnylam's guide notes no post-injection observation period in the US label. | Administration Guide |
Monitoring the Amvuttra label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Baseline and ongoing | No laboratory test required by the label | Alnylam's administration guide states laboratory monitoring is not required | Administration Guide |
| Throughout | Vitamin A supplementation at the RDA | Do not dose above the RDA to normalize serum vitamin A; serum levels do not reflect total body stores. HELIOS-B: 82% normal at baseline, 80% of those went low; mean steady-state reduction 65% over 36 months | FDA label |
| Any time | Ocular symptoms suggestive of vitamin A deficiency, such as night blindness | Refer to an ophthalmologist | FDA label |
| Any time | Conduction | HELIOS-A recorded 2 serious AV block reactions (1.6%), one complete; the label gives no monitoring instruction. At 12 times the dose, no clinically relevant QT prolongation | FDA label |
| After each dose | Injection site | Reactions in 4% in HELIOS-A, mild and transient: bruising, erythema, pain, pruritus, warmth | FDA label |
| Response | Outcomes the label reports at month 30 | 6MWT difference 22m and KCCQ-OS 6 points favoring vutrisiran overall; NT-proBNP and troponin I favored vutrisiran. FEP renewal asks for improvement or stability on such measures | FDA label |
| Pharmacodynamics | Serum TTR | Mean steady-state reduction 83% in HELIOS-A; HELIOS-B similar and consistent across subgroups including baseline tafamidis use | FDA label |
Amvuttra drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Contraindications | None | FDA label |
| CYP enzymes and transporters | No clinical interaction studies. In vitro, not a CYP substrate or inhibitor, and not expected to induce CYP enzymes or modulate transporters. Metabolized by nucleases in the liver | FDA label |
| Tafamidis | No label restriction. HELIOS-B stratified by baseline tafamidis (40%); 22% of the vutrisiran arm and 21% of placebo started open-label tafamidis, median 18 months in. Primary composite HR 0.72 overall, 0.67 in the monotherapy population | FDA label |
| Billing code | HCPCS J0225, injection, vutrisiran, 1mg, per the Cigna policy's coding table | Cigna policy |
| Payer rule on combinations | Cigna: concurrent Attruby, tafamidis, Onpattro, Tegsedi or Wainua is not medically necessary, citing a lack of controlled data for additive efficacy | Cigna policy |
| Vitamin A products | Supplement at the RDA only; review multivitamins and other vitamin A sources for the total | FDA label |
| Immunogenicity | Transient low-titer anti-drug antibodies in 2.5% (HELIOS-A) and 0.3% (HELIOS-B); effect on PK or PD not determinable | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedA new patient whose request is denied, or still pending 7 calendar days after it was sent, may get one dose free through the Alnylam Assist Quick Start Program. The office needs a Start Form on file first, and a licensed provider signs the request.
- The plan wants more recordsPlans such as Cigna ask for how the diagnosis was confirmed, heart imaging that shows involvement, and the symptom class. The cardiologist's records usually settle it, and the Case Manager keeps you updated on the appeal.
- The plan will not pay alongside tafamidis or AttrubyCigna's policy treats Amvuttra given with tafamidis, Attruby or another ATTR drug as not medically necessary. The label does not bar the combination. The cardiologist's office decides whether to appeal or change the plan of treatment.
- The place of the injection is not coveredA home dose depends on insurance, and some plans limit where a dose can be given. The Case Manager can send a list of treatment sites that your coverage accepts.
- Your insurance changed partway throughThe Alnylam Assist Bridge Program supplies medicine to eligible patients whose coverage changes and delays a dose. A Case Manager checks eligibility once a Start Form is on file.
- A cost you cannot payCommercial insurance: the Alnylam Assist Copay Program, which covers certain out-of-pocket costs. People on Medicare, Medicaid or other government plans cannot use it. Alnylam says most Medicare patients have coverage, and its Patient Assistance Program gives the drug free to eligible people, mainly the uninsured.
Alnylam Assist
- Alnylam Case Managers who verify your insurance coverage, check whether you qualify for financial help and work to keep you on Amvuttra, once your doctor sends a Start Form
- The Alnylam Assist Copay Program, which covers certain out-of-pocket costs for eligible people with commercial insurance, not for Medicare, Medicaid or other government plans
- Programs that may help during a delay or gap in coverage, with eligibility set by a Case Manager
- The Alnylam Assist Patient Assistance Program, which may give Amvuttra at no cost to eligible people, mainly the uninsured
- Patient Education Liaisons, Alnylam employees who help you understand the disease and answer questions about Amvuttra but are not part of your care team
Questions prescribers' offices ask about Amvuttra
What is the Amvuttra dose for ATTR-CM?
The March 2025 label sets 25mg by subcutaneous injection once every 3 months, administered by a healthcare professional, with no titration and no dose adjustment for age, mild or moderate renal impairment, or mild or moderate hepatic impairment. A missed dose is given as soon as possible, and dosing resumes every 3 months from the most recent dose.
What does the label say about vitamin A on Amvuttra?
The March 2025 label advises supplementation at the recommended daily allowance of vitamin A for all patients and says higher doses should not be given to normalize serum levels, which do not reflect total body vitamin A. In HELIOS-B, 80% of patients with a normal baseline developed low levels, and mean serum vitamin A fell 65% over 36 months. Refer to an ophthalmologist for ocular symptoms suggestive of deficiency, such as night blindness.
Does Amvuttra require a REMS or laboratory monitoring?
Neither, under the March 2025 label, which has no boxed warning, no contraindications and no REMS. Alnylam's administration guide states that premedication and laboratory monitoring are not required and that the label recommends no post-injection observation period.
Can Amvuttra be given with tafamidis?
The March 2025 label does not restrict concomitant use; in HELIOS-B, 40% of patients were on tafamidis at baseline and 22% of the vutrisiran arm started it during the study. The 28% reduction in the primary composite was in the overall population, and the monotherapy population showed 33%. Cigna's policy, effective April 15, 2026, classes concurrent use with tafamidis or Attruby as not medically necessary.
What do insurers ask for to approve Amvuttra for ATTR-CM?
The Cigna policy on this page, effective April 15, 2026, after the March 2025 label, asks for age 18 or older and a diagnosis confirmed by technetium pyrophosphate scintigraphy, biopsy with TTR typing, or a pathogenic TTR variant. It also asks for imaging showing cardiac involvement, heart failure short of NYHA class IV, a cardiologist or amyloidosis specialist, and no concurrent tafamidis, Attruby or silencer. Approval runs 1 year.
Free email alert
Get an email when the Amvuttra label changes
One email the day the FDA revises the Amvuttra prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Amvuttra only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- AMVUTTRA (vutrisiran) injection, for subcutaneous use, Revised: 3/2025, Alnylam Pharmaceuticals, via DailyMed, 2025-11-06.
- AMVUTTRA® (vutrisiran) Dosing and Administration Guide (AMV-USA-00071-V3), Alnylam Pharmaceuticals, 2026-11-07.
- Taking AMVUTTRA | AMVUTTRA® (vutrisiran), Alnylam Pharmaceuticals, 2026-11-07.
- Coverage & Starting Treatment | AMVUTTRA® (vutrisiran) | Alnylam Assist®, Alnylam Pharmaceuticals, 2026-11-07.
- Support & Education Teams | AMVUTTRA® (vutrisiran) | Alnylam Assist®, Alnylam Pharmaceuticals, 2026-11-07.
- Support & Education Teams | AMVUTTRA® (vutrisiran) | Alnylam Assist® HCP, Alnylam Pharmaceuticals, 2026-11-07.
- Financial Assistance & Support | AMVUTTRA® (vutrisiran), Alnylam Pharmaceuticals, 2026-11-07.
- Financial Assistance | AMVUTTRA® (vutrisiran) | Alnylam Assist® HCP, Alnylam Pharmaceuticals, 2026-11-07.
- Alnylam Assist® Copay Program Enrollment, Terms and Conditions, Alnylam Pharmaceuticals, 2026-11-07.
- Alnylam Assist® Start Form, AMVUTTRA® (vutrisiran) (AMV-USA-00015-V6), Alnylam Pharmaceuticals, 2026-11-07.
- Alnylam Assist® Quick Start Program enrollment form (AMV-USA-01095-V3), Alnylam Pharmaceuticals, 2026-11-07.
- AMVUTTRA® (vutrisiran) Product Characteristics (AMV-USA-00034-V4), Alnylam Pharmaceuticals, 2026-11-07.
- Drug Coverage Policy IP0478, Amyloidosis – Amvuttra, Cigna, 2026-04-15.
- 5.75.037, Prescription Drugs, Amvuttra, Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- NDA 215515/S-006 supplement approval letter, cardiomyopathy indication, FDA, 2025-03-20.
- NDA 215515/S-005 supplement approval letter, section 13.1 mouse carcinogenicity, FDA, 2025-03-11.
- NDA 215515/S-002 supplement approval letter, sections 6.1 and 13.1, FDA, 2023-02-16.
- NDA 215515 approval letter, FDA, 2022-06-13.
A reference drawn from the November 6, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.